Neoadjuvant trial of Ganetespib shows promise for TNBC and HER2+ BC

Can not tell how durable is the response from the neoadjuvant study, but the response rate is phenomenal, especially when considering the abysmal record of TNBC treatmnet.
http://www.heraldonline.com/2013/07/29/5061751/synta-announces-enchant-1-breast.html


Ganetespib also shows good performance against some types of lung cancer:
http://medicalxpress.com/news/2012-01-ganetespib-kras-mutant-nsclc-monotherapy-combinations.html

It's possible that the cure for BC requires combo of several targetted therapies at the same time.